Wan Tai Biology: Net loss of 144 million yuan in the first half of the year, turning from profit to loss year-on-year.

Wantaibio announces that in the first half of 2025, the operating income was 844 million yuan, a year-on-year decrease of 38.25%; the net profit attributable to shareholders of the listed company was a loss of 144 million yuan, a year-on-year turn to a loss. The company stated that the decrease in operating income was mainly due to factors such as market competition affecting the sales of the bivalent cervical cancer vaccine, which did not meet expectations.